Company Illustrated Its Scientific and Clinical Leadership
in Transforming the Future of Children’s Vision
ROCHESTER, N.Y., November 18, 2024—CooperVision's leadership and commitment to transforming the trajectory of myopia in children was prominently showcased at the prestigious 60th International Myopia Conference (IMC) events in Changsha and Sanya, China. Research findings spanned the company’s comprehensive range of optical interventions, including MiSight® 1 day* soft contact lenses.
“Our dedication to advancing the science and practice of myopia management was on full display at IMC, as teams from CooperVision and our research partners around the globe debuted significant new studies,” said Elizabeth Lumb, BSc (Hons) MCOptom, FIACLE, FBCLA, Director of Global Professional Affairs, Myopia Management, CooperVision.
More than a dozen CooperVision authored and supported papers and posters were accepted to this year’s conference, including Myopia Control with MiSight® 1 day Dual Focus Lenses in Chinese Children (Arumugam B, et al).1 Interim results from an ongoing, double-masked, multi-center randomized clinical trial in China showed considerable efficacy of MiSight® 1 day in slowing myopia progression.1 The absolute treatment effects for both axial length and cycloplegic refractive error in children enrolled at ages 7 to 11 were even greater than those observed previously in a majority non-Asian cohort (Chamberlain, et al 2019).1,2
Additional CooperVision-supported papers and posters included an analysis of myopia control prescribing patterns in the U.S., Australia, and New Zealand, and research regarding the potential irradiance hazards of red-light therapy. Extended efficacy data for SightGlass Vision spectacle lenses with Diffusion Optics Technology™,† advanced through a joint venture between CooperVision and EssilorLuxottica, was also presented.
The company also showcased multiple category experts through its digital platforms throughout the week, including LinkedIn. Researchers and program team members who have been instrumental in developing, sharing, and promoting invaluable myopia control and management science—work that is changing the lives of children worldwide—reflected on their work and its impact.3,4
Learn more at https://www.linkedin.com/company/coopervision.
For more details on the 2024 IMC, visit www.internationalmyopiaconference.org.
###
*Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
† This product is not approved in all markets.
1. Arumugam B et al. Myopia Control with MiSight® 1 day Dual Focus Lenses in Chinese Children. Poster presentation. IMC Hainan, China, Sep 2024.
2. Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. Optom Vis Sci. 2019; 96(8):556-567.
3. E. L. Lamoureux, J. Wang, T. Aung, S. M. Saw, T. Y. Wong; Myopia and Quality of Life: The Singapore Malay Eye Study (SiMES). Invest. Ophthalmol. Vis. Sci. 2008;49(13):4469.]
4. Chua S.Y.L., Foster P.J. (2020) The Economic and Societal Impact of Myopia and High Myopia. In: Ang M., Wong T. (eds) Updates on Myopia. Springer, Singapore.
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq: COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week, and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and irregular corneas; and offers the most complete portfolio of spherical, toric, and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women’s health company dedicated to assisting women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000 with products sold in over 130 countries. For more information, visit www.coopercos.com.
Media Contact
Laura DiCaprio, Senior Counselor
McDougall Communications for CooperVision
Laura@mcdougallpr.com or +1-585-434-2153